Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Morningside Sets Up China Cancer JV with Can-Fite

publication date: Jan 20, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Morningside Asia Venture, the Hong Kong venture capital firm, signed a memorandum of understanding to establish a China joint venture with Can-Fite BioPharma, an Israeli company. Morningside will pay $7.5 million to Can-Fite for the China rights to CF102, a drug being developed to fight liver cancer. The money will underwrite all expenses of the JV through Phase II clinical trials. More details...

Stock Symbol: (TASE: CFBI)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...